<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04491435</url>
  </required_header>
  <id_info>
    <org_study_id>FF2018-133</org_study_id>
    <nct_id>NCT04491435</nct_id>
  </id_info>
  <brief_title>Saliva Substitute Mouthwash in NPC Survivors With Xerostomia: A Randomized Controlled Trial</brief_title>
  <official_title>Saliva Substitute Mouthwash in NPC Survivors With Xerostomia: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universiti Kebangsaan Malaysia Medical Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universiti Kebangsaan Malaysia Medical Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nasopharyngeal carcinoma (NPC) is the highest reported otorhinolaryngological malignancy&#xD;
      reported in Malaysia affecting predominantly male adults between 40-60 years old [1, 2].&#xD;
      Radiation therapy (RT) has been coined as the mainstay treatment owing to its' radiosensitive&#xD;
      properties [1, 3]. Radiation-induced DNA damage impairs proper cell division, resulting in&#xD;
      cell death or senescence of cells that attempt to divide, particularly useful in killing&#xD;
      malignant cells. However, radiation doses to the salivary glands cause loss of saliva&#xD;
      producing acinar cells which ultimately hampers production of saliva in NPC patients post&#xD;
      radiation [4]. This leads to progressive loss of salivary gland function causing xerostomia&#xD;
      symptoms [5]. This study aims to compare the effects of two mouthwashes in the treatment of&#xD;
      xerostomia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Xerostomia, or dry mouth caused by reduced or absent saliva flow, is a subjective symptom&#xD;
      that can lead to impaired chewing, swallowing, altered sense of taste and speech. This&#xD;
      eventually affects their nutritional status and quality of life. The reported prevalence of&#xD;
      xerostomia in NPC survivors ranged from 80% -100% [6-9]. This high prevalence has stemmed a&#xD;
      lot of interest in prevention and treatment of this important sequelae. Saliva substitute in&#xD;
      the forms of gels, toothpaste, sprays or mouthwash has been used for treatment of xerostomia&#xD;
      [10]. Oral7® mouthwash (Oral7 International, United Kingdom) is a mucin-based saliva&#xD;
      substitute formulated with natural enzymes such as lactoperoxidase, lysozyme, glucose oxidase&#xD;
      and lactoferrin, similar to naturally occuring saliva. The biophysical properties of the&#xD;
      mouthwash can potentially provide relief to xerostomia symptoms in patients post radiotherapy&#xD;
      translating to a better quality of life. Hence, the purpose of the present study is to&#xD;
      evaluate the effects of saliva substitute in treating xerostomia among NPC patients post&#xD;
      radiotherapy. The primary end-point of the study was to compare the subjective xerostomia&#xD;
      symptoms, measured using a validated inventory taken 4 weeks following intervention and at&#xD;
      baseline between patients who did not receive and patients who received Oral7® mouthwash. The&#xD;
      secondary end-point was to demonstrate similar changes in objective measurements using&#xD;
      sialometry techniques.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 5, 2018</start_date>
  <completion_date type="Actual">March 5, 2020</completion_date>
  <primary_completion_date type="Actual">January 5, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Participants and outcome assessor blinded to allocation of treatment, which was only revealed after completion of data collection</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>summated xerostomia inventory (SXI) score</measure>
    <time_frame>4 weeks</time_frame>
    <description>summated xerostomia inventory (SXI) score at baseline-summated xerostomia inventory (SXI) score at 4 weeks post intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>unstimulated whole saliva (UWS) flow</measure>
    <time_frame>4 weeks</time_frame>
    <description>unstimulated whole saliva (UWS) flow at 4 weeks post intervention -unstimulated whole saliva (UWS) flow at baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Xerostomia, Hyposalivation, Saliva Substitute, Radiation-induced Toxicity, Nasopharyngeal Cancer</condition>
  <arm_group>
    <arm_group_label>Interventional</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 weeks use of mucin-based saliva substitute</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 weeks use of xylitol-based mouthwash</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Summated Xerostomia Inventory</intervention_name>
    <description>structured interview by a dedicated researcher to obtain a score of the summated xerostomia inventory (SXI)</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Interventional</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Sialometry</intervention_name>
    <description>unstimulated whole saliva (UWS) flow measurement</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Interventional</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have completed radiation therapy or concurrent chemotherapy and radiation&#xD;
             therapy for nasopharyngeal carcinoma (clinical staging of tumour based on AJCC staging&#xD;
             (8th edition) T1-4, N0-3, M0).&#xD;
&#xD;
          -  Patients age 20 years old to 85 years old.&#xD;
&#xD;
          -  Two months has elapsed since last dose of chemotherapy or radiotherapy&#xD;
&#xD;
          -  Karnofsky performance score more than 70%.&#xD;
&#xD;
          -  Patients complaining of xerostomia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those contraindicated to using mouthwash (established allergy to lactoperoxidase,&#xD;
             lysozyme, glucose oxidase lactoferrin, cetylpyridinium chloride and xylitol)&#xD;
&#xD;
          -  Patients with residual or recurrent disease.&#xD;
&#xD;
          -  Patients who received intensity modulated radiation therapy.&#xD;
&#xD;
          -  Patients with ongoing oral mucositis (WHO Oral Mucositis grading I to IV)&#xD;
&#xD;
          -  Patients with facial, glossopharyngeal. vagus and hypoglossal nerve palsy/ paresis.&#xD;
&#xD;
          -  Patients who had any form of concurrent treatment protocols (hormonal, alternative,&#xD;
             antiviral, sialogogues or photodynamic therapy) during the study duration.&#xD;
&#xD;
          -  Patients with autoimmune diseases such as systemic lupus erythematosus, rheumatoid&#xD;
             arthritis and Sjớgren syndrome.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mawaddah Azman, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University of Malaysia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universiti Kebangsaan Malaysia Medical Centre</name>
      <address>
        <city>Cheras</city>
        <state>Kuala Lumpur</state>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <reference>
    <citation>Gravenmade EJ, Vissink A. Mucin-containing lozenges in the treatment of intraoral problems associated with Sjögren's syndrome. A double-blind crossover study in 42 patients. Oral Surg Oral Med Oral Pathol. 1993 Apr;75(4):466-71.</citation>
    <PMID>8464611</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 24, 2020</study_first_submitted>
  <study_first_submitted_qc>July 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Xerostomia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will be shared upon publication of the research</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

